Skip to main content
. 2017 Apr 11;116(10):1271–1278. doi: 10.1038/bjc.2017.93

Figure 3.

Figure 3

Survival curves. Progression-free survival in the three different treatment arms: (A) RAS- and BRAF-tested population; (B) RAS and BRAF wild-type population. Progression-free survival from start of treatment cycle 9 in arms A (FLOX) and C (maintenance treatment with cetuximab) in patients with (C) RAS/BRAF wild-type tumours and (D) RAS-mutated tumours. CI=confidence interval; HR=hazard ratio.